Generic Ciclesonide 200mdi Inhaler: Useful to treat Asthma
![Image](https://www.apsense.com/blog_photo/20240228/1709185303764747.jpg)
Ciclesonide, an inhaled corticosteroid can treat mild to severe forms of asthma. Its action mechanism and formulation yield low systemic and oral bioavailability and high pulmonary deposition. Studies concluded that it is effective enough to control symptoms similar as budesonide or fluticasone propionate. In a few cases, it shows improved tolerability and safety outcomes.
Asthma
Society is suffering from asthma problems in terms of healthcare costs, quality of life, mortality, and morbidity. Asthma rates the world over, especially among children have set new records. It has been affecting children between 1 and 17 years. AS first-line therapy, doctors recommend ICS (Inhaled corticosteroids) to treat asthma. It also improves airway inflammation markers and asthma symptoms.
About Ciclesonide
It can treat severe to mild persistent asthma. MDI (metered dose inhaler) is used to deliver this medicine. Daily dosage once or twice as suggested by the doctor. Hydrofluoroalkalne-MDI is used to inhale it into the lungs. Here, local esterases convert it into desisobutyryl-ciclesonide, an active metabolite. Des-CIC has 1212 higher binding affinity. On the other hand, CIC has 12 low glucocorticoid binding affinity.
Studies conducted
Des-CIC pharmacokinetic profiles were similar in asthma patients and healthy people. It indicates that airway inflammation and bronchial narrowing did not affect CIC distribution, including its subsequent activation inside the lungs to des-CIC. Studies also revealed CIC-HFA in equivalent PK/PD profiles when administered with/without the spacer.
Placebo-controlled
Ciclesonide’s therapeutic action is achieved once esterases in the lungs cleave inhaled parent compound to an active metabolite. The latter is a corticosteroid having high anti-inflammatory activity and receptor affinity. Anti-inflammatory properties were noted in patients suffering from persistent, mild asthma. Generic ciclesonide 200mdi inhaler proved to be a real savior. Doctors usually prescribe the medicine based on the patient’s circumstance and health condition.
Controlling symptoms
Studies demonstrated that using CIC for treatment enhances symptom control in asthma patients treated earlier with another ICS. Besides this, significant FEV improvement took place in severe to moderate asthmatics provided with appropriate CIC daily. The results obtained were favourable when compared to placebo treatments requiring the patient to have a much higher dosage and more recovery time.
Treating children
Studies were conducted among children between ages 4 and 11 suffering from severe to mild persistent asthma attacks. A study was conducted to identify the effect of CIC’s multiple strengths on children. The subjects were initially randomized to 1 of 3 placebos or CIC treatments once daily. CIC doses saw a significant FEV increase compared to placebo. Reports state CIC offers better results than Placebo.
Comparative studies
Once daily, CIC dosage is a better cure for asthma attacks when compared to other common ICS to treat asthma problems like FP and BUD. A single daily dosage administered in the evening or morning demonstrated greater efficacy. Single daily dosage effectiveness can help improve symptom control while complying with patients’ prescribed asthma control therapy like CIC.
A safe approach
CIC is a safe and novel ICS that doctors prescribe to patients experiencing asthmatic attacks. You may order it online at completeonlinepharmacy.com using your doctor’s prescription.
Comments